eGenesis is a Cambridge, Massachusetts clinical-stage biotechnology company using multiplex CRISPR gene editing to engineer pig organs that the human body will accept. Its EGEN platform makes dozens of edits to a porcine genome at once - removing pig antigens, adding human genes, and inactivating embedded retroviruses - to create kidneys, livers, and hearts intended to ease the global organ shortage. In 2024 its lead candidate became the basis of the world's first gene-edited pig kidney transplant in a living patient, and in 2025 the FDA cleared it for a formal clinical trial.
Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.